New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2014
07:14 EDTSNTASynta Pharmaceuticals reports Q1 EPS 28c, consensus 29c
The company said, "There were no revenues recognized in 1Q14 and 1Q13. Research and development expenses were $17.6M for Q1." Reports Q1 General and administrative expenses $5.3M. Q1 revenue consensus $450K.
News For SNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
08:04 EDTSNTASynta Pharmaceuticals to present results from Phase 1 trial of Ganetespib
Subscribe for More Information
December 11, 2014
08:05 EDTSNTAFDA Pediatric Oncologic Subcommittee to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use